Keystone Symposia Conference | New Paradigms in Cancer Therapeutics

Meeting Program

To view program in "24 hour" time (international) click here.

Tuesday, March 23
3:00 - 7:30 PM	Registration	Prefunction 2
6:30 - 7:30 PM	Refreshments	Prefunction 2
7:30 - 8:30 PM	Keynote Address (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B-C
	Hans C. Clevers, Hubrecht Institute, The Netherlands Wnt, Lgr5 Stem Cells and Cancer
Wednesday, March 24
7:00 - 8:00 AM	Breakfast	Palm Court
8:00 - 11:15 AM	Epigenetic Targets in Cancer Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B
	Danny F. Reinberg, NYU-School of Medicine, USA EZH2 and Histone Methylatransferases as Targets in Cancer
	Thea D. Tlsty, University of California, San Francisco, USA Talk Title to be Determined
	Peter A. Jones, University of Southern California, USA Cancer Epigenomics
	Jean-Pierre Issa, University of Texas MD Anderson Cancer Center, USA Combinations Targeting Multiple Epigenetic Pathways
	Akihide Yoshimi, Graduate School of Medicine, University of Tokyo, Japan Short Talk: EVI1 Induces a Novel Epigenetic Regulation of PTEN/AKT/mTOR Signaling through Interaction with Polycomb Complexes in Leukemia
	Aliaksei Holik, Cardiff University, UK Short Talk: Chromatin Remodelling ATPase Brg-1 is an Essential Factor for the Maintenance of the Intestinal Crypt Stem Cell and Wnt Driven Adenoma Formation
Following Session is for Signaling Pathways (Z2)
8:00 - 11:00 AM	Integrating Signal Gradients in Development Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010 Hh vs. Wnt or TGFbeta, Notch, etc. in developing Neural Tube, Fly Wing Imaginal Disc., A/P or D/V Polarity etc.; Classical and Newer Work to Set Tone	Salon C


	Jean-Denis Benazet, University of Basel, Switzerland Talk Title to be Determined


	Xi He, Harvard Medical School, USA Mechanisms of Wnt Signaling and Regulation
	Brandon J. Wainwright, University of Queensland, Australia The Intersection between Hedgehog and Notch Signaling in Development and Cancer

	Feng Cong, Novartis Institutes for BioMedical Research, USA Short Talk: Targeting Wnt Signalling through TNKS Inhibition and Axin Stabilization
9:20 - 9:40 AM	Coffee Break	Prefunction 2
11:15 AM-	On Own for Lunch and Recreation
11:15 AM- 1:00 PM	Poster Setup	Salon A
1:00 - 10:00 PM	Poster Viewing	Salon A
4:30 - 5:00 PM	Coffee Available	Prefunction 2
5:00 - 7:00 PM	Predictive Signatures for Cancer Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B
	Levi A. Garraway, Dana Farber Cancer Institute, USA High-Throughput Oncogene Mutation Profiling in Human Cancer
	Joe W. Gray, Lawrence Berkeley National Laboratory, USA Omics Based Approaches to Predict Cancer Therapy
	William R. Sellers, Novartis Institutes for BioMedical Research, USA Connecting Patients to Therapy: Functional and Comparative Approaches to Translational Oncology
	Daniel R. Rhodes†, University of Michigan, USA Short Talk: Somatic Mutations in Human Cancer Cell Lines Predict Sorafenib Response
Following Session is for Signaling Pathways (Z2)
5:00 - 7:00 PM	Mechanisms of Signal Integration I - Hippo Pathway and Cilia Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon C
	Jeremy F. Reiter, University of California, San Francisco, USA Primary Cilia Transduce Hedgehog Signals in Both Development and Cancer
	Elaine Fuchs, Howard Hughes Medical Institute, Rockefeller University, USA Developmental Signaling Pathways in the Skin

	Helen McNeill, Samuel Lunenfeld Research Institute, Canada Fat Cadherins in the Regulation of Growth and Planar Cell Polarity
	Rhonda Hui Ping Kan, Institute for Molecular Bioscience, Australia Short Talk: N-myc and C-myc are Functionally Redundant in Mediating the Effects of Ptch1 Mutation in Epidermis
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Salon A
7:30 - 10:00 PM	Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon A
Thursday, March 25
7:00 - 8:00 AM	Breakfast	Palm Court
8:00 - 11:15 AM	Targeting Developmental Pathways in Cancer (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B-C
	Joseph Kelleher, Novartis, USA Hedgehog Inhibitors
	Paul G. Polakis, Genentech, Inc., USA Wnt Antagonists in Cancer
	A. Thomas Look, Dana-Farber Cancer Institute, USA Activating Mutations in the ALK Tyrosine Kinase Provide a Therapeutic Target in Neuroblastoma
	Luisa Iruela-Arispe, University of California, Los Angeles, USA Angiogenesis, Developmental Pathways and Cancer
	James F. Amatruda, University of Texas Southwestern Medical Center, USA Short Talk: BMP Signaling in Germ Cell Differentiation and Germ Cell Tumors
	Leni S. Jacob, University of Texas Southwestern Medical Center, USA Short Talk: Assignment of Aberrant Hedgehog and Wnt Pathway Activity to Disease by Genome-Wide RNAi in Cultured Cells
9:20 - 9:40 AM	Coffee Break	Prefunction 2
11:15 AM-	On Own for Lunch and Recreation
11:15 AM- 1:00 PM	Poster Setup	Salon A
1:00 - 10:00 PM	Poster Viewing	Salon A
4:30 - 5:00 PM	Coffee Available	Prefunction 2
5:00 - 7:00 PM	Recurrent Gene Fusions as Cancer Therapeutic Targets Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B
	Hiroyuki Mano, University of Tokyo/Jichi Medical University, Japan Targeting the ALK Fusion Genes in Lung Cancer
	Arul M. Chinnaiyan, University of Michigan, USA Targeting Gene Fusions in Prostate Cancer
	Yardena Samuels, NHGRI/NIH, USA Mutational Analysis of the Melanoma Genome
	Yoshihiro Yamashita, Jichi Medical University, Japan Short Talk: Array-based Genomic Resequencing of Acute Myeloid Leukemia
Following Session is for Signaling Pathways (Z2)
5:00 - 7:00 PM	Mechanisms of Signal Integration II - Coordinated Proteolysis Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon C
	Randall T. Moon, University of Washington School of Medicine, USA Elucidating Wnt/beta-Catenin Signaling Networks by Integrated siRNA, Proteomic, and Small Molecule Screens
	Jin Jiang, University of Texas Southwestern Medical Center, USA Kinase Regulation of Hedgehog Signaling


	Ying E. Zhang, National Cancer Institute, National Institutes of Health, USA Proteolysis in TGF-beta Signaling and Cancer
	Masahiro Narimatsu, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Canada Short Talk: Smurf Ubiqutin Ligases are Required for Embryo Patterning during Gastrulation
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Salon A
7:30 - 10:00 PM	Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon A
Friday, March 26
7:00 - 8:00 AM	Breakfast	Palm Court
8:00 - 11:15 AM	Towards Rational Targeted Combination Therapy Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B
	Kenneth P. Nephew, Indiana University, USA DNA Methylation Inhibitors for Chemotherapy Resensitization of Solid Tumors
	Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA Talk Title to be Determined
	Marion B. Dorsch, Novartis Institutes for BioMedical Research, USA Smoothened Anatgonists: Anticipating and Treating Resistance
	Shaomeng Wang, University of Michigan, USA Current Targeting of Multiple Key Apoptosis Regulators is Required to Efficiently Kill Tumor Cells
	Caroline M. Emery, Dana Farber Cancer Institute, USA Short Talk: Genetic Studies of Resistance to MEK and BRAF Inhibition
	Jinyan Du, Broad Institute, USA Short Talk: Systematic Characterization of Pathway Interactions with ER Signaling in Human Mammary Carcinomas
Following Session is for Signaling Pathways (Z2)
8:00 - 11:00 AM	Mech of Integration III - Transcriptional Regulation and/or Epigenetics/Reversible Histone Methylation Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon C

	Michael D. Taylor, Hospital for Sick Children, Canada A Role for Histone Lysine Methylation in the Pathogenesis of Pediatric Brain Tumors?

	Nimet Maherali, Massachusetts General Hospital, USA Understanding Nuclear Reprogramming and Pluripotency
	Ken M. Cadigan, University of Michigan, USA Selection of Wnt Targets and Subsequent Chromatin Modifications
	Richard S. Mann, Columbia University, USA Talk Title to be Determined

	Felix Lohmann, Novartis Institutes for BioMedical Research, USA Short Talk: KMT1E Mediated H3K9 Methylation is Required for the Maintenance of Embryonic Stem Cells by Repressing Trophectoderm Differentiation
9:20 - 9:40 AM	Coffee Break	Prefunction 2
4:30 - 5:00 PM	Coffee Available	Prefunction 2
5:00 - 7:00 PM	Targeting Metabolic Pathways in Cancer Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B
	Matthew G. Vander Heiden, Harvard University, USA Targeting Cancer Cell Metabolism
	Craig B. Thompson, Abramson Family Cancer Center and Research Institute, University of Pennsylvania, USA Therapeutic Exploitation of Metabolomic Differences between Normal and Cancer Cells
	Valeria Fantin, Agios Pharmaceuticals, USA Cancer-Associated IDH1 Mutations Produce 2-Hydroyxglutarate
	Amjad Pervez Khan, University of Michigan, USA Short Talk: Metabolomic Profiling Delineate Polyamines as Biomarkers for Prostate cancer Progression
Following Session is for Signaling Pathways (Z2)
5:00 - 7:00 PM	Stem Cell Fate and Signaling Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon C
	Jim Woodgett, Mount Sinai Hospital, Canada Coordinate Regulation of Multiple Signaling Pathways and Differentiation Processes by Glycogen Synthase Kinase-3
	Austin G. Smith, University of Cambridge, UK Intrinsic and Extrinsic Regulation of the Pluripotent Ground State

	Jeffrey L. Wrana, Mount Sinai Hospital, Canada Cell Fate and Polarity Signals
	Rita U. Lukacs, University of California, Los Angeles, USA Short Talk: Bmi-1 is a Dominant Self-Renewal Gene in the Murine Prostate that Controls both Stem Cell Maintenance and Cancer Initiation
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Salon A
Saturday, March 27
7:00 - 8:00 AM	Breakfast	Palm Court
8:00 - 11:00 AM	siRNA Therapeutics Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B
	Daniel G. Anderson, Massachusetts Institute of Technology, USA Combinatorial Development of Biomaterials and Synthetic siRNA Delivery Systems
	Ian MacLachlan, Tekmira Pharmaceuticals Corp., Canada Therapeutic Silencing of Polo-Like Kinase 1 and Kinesin Spindle Protein via the Confirmed Mechanism of RNA Interference
	John J. Rossi, Beckman Research Institute of the City of Hope, USA Strategies for RNA Interference (RNAi) Applications in Cancer Therapy
	Eric G. Marcusson, Regulus Therapeutics, USA Short Talk: microRNA Mimics as Cancer Therapeutics
	Steven Blake, University of North Carolina at Chapel Hill, USA Short Talk: Targeted Delivery of siRNA using PRINT® particles
	Kathy L. Fosnaugh†, MDRNA, Inc., USA Short Talk: Development of siRNA Therapeutics for Treatment of Bladder Cancer and Hepatocellular Carcinoma
Following Session is for Signaling Pathways (Z2)
8:00 - 11:00 AM	Integrated Signaling in Tumor/Stromal Interaction Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010 Emerging stories around tumors and stroma feeding each other signals and each changing to reinforce cancer.	Salon C

	Morag Park, McGill University, Canada Talk Title to be Determined
	John Condeelis, Albert Einstein College Of Medicine, USA The Tumor Microenvironment Invasion Signature: Effects on Tumor Cell Plasticity in vivo
	Christine Dierks, Genomics Institute of the Novartis Research Foundation, USA Hedgehog Signaling in Hematologic Malignancies
	Minoti Apte, University of New South Wales, Australia Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells
	Gabri Van der Pluijm†, Leiden University Medical Center, The Netherlands Short Talk: TGFâ-BMP7 Interactions in Bone Metastasis; Potential Therapeutic Implications
9:20 - 9:40 AM	Coffee Break	Prefunction 2
11:00 AM-	On Own for Lunch and Recreation
4:30 - 5:00 PM	Coffee Available	Prefunction 2
5:00 - 7:00 PM	Novel Biologic and Virus Based Cancer Therapeutics Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon B
	Gregory L. Verdine, Harvard University, USA Drugging Oncogenic Transcription Factors
	Serge Muyldermans, Vrije Universiteit Brussel, Belgium Camelid Nanobodies for Cancer and Diagnostic Assay Development
	Patrick A. Baeuerle, Micromet, Inc., USA Engaging T Cells for Cancer Therapy by Bispecific Antibodies
	Sunjoo Jeong, Dankook University, South Korea Short Talk: RNA Aptamers for the Modulation of Wnt/beta-catenin Signaling
Following Session is for Signaling Pathways (Z2)
5:00 - 7:00 PM	Aberrant Signal Interactions and Disease Registered attendees for this meeting can view Abstracts for this session starting on 02/23/2010	Salon C

	Geraldine Weinmaster, David Geffen School of Medicine at UCLA, USA Ligand Endocytosis and Force Generation in Activation of Notch Signaling
	Bruce A. Edgar, Zentrum für Molekulare Biologie University of Heidelberg, Germany Signaling and Stem Cell Control in the Drosophila Intestine
	Adolfo Ferrando, Columbia University, USA NOTCH1 Transcriptional Networks in Human Leukemia
	Daniela Quail, University of Western Ontario, Canada Short Talk: Nodal Promotes Metastasis and Stem Cell Phenotypes in Breast Cancer
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Palm Court
8:00 - 11:00 PM	Entertainment	Palm Court
Sunday, March 28
	Departure
*=Session Chair †=Speaker invited, not yet responded.

Keystone Symposia would like to thank the sponsors of this meeting for their generous support:

We gratefully acknowledge additional support for this conference from:



Tekmira

The Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

We gratefully acknowledge the organizations that provide Keystone Symposia with additional support, such as marketing and advertising...

Click here to view these companies

The advent of genome-scale profiling technologies has opened up the possibility of comprehensively monitoring multiple layers of molecular aberrations in cancer. Alterations in the epigenome, genome, transcriptome, proteome and metabolome have all been observed in tumor development. A number of key molecular pathways have been found to be altered during cancer progression. Pivotal questions in the field include: Can these novel pathways alone or in combination be effectively targeted in cancer? Can we identify molecular signatures that will facilitate personalized medicine? What are the innovative therapeutic modalities that can be employed to target these pathways? The goal of this meeting is to tackle promising new targets for cancer therapy. These include targets such as recurrent gene fusions, epigenetic pathways, and metabolic networks. We will also explore the use of molecular marker panels to select patients for treatment. A number of approaches to therapeutic targeting will be discussed including novel biologics and RNA interference.

New Paradigms in Cancer Therapeutics (Z1)